Can-Fite BioPharma, Ltd. is a biotechnology company developing drugs for treating cancer and autoimmune inflammatory diseases. Principally, the company develops CF101, which is in Phase III study for the treatment of psoriasis and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, Phase III study for the treatment of dry eye, and Phase I study for the treatment of uveitis. For more information, visit the company’s website at www.canfite.co.il.